127 related articles for article (PubMed ID: 8723690)
1. Six novel mutations in the fumarylacetoacetate hydrolase gene of patients with hereditary tyrosinemia type I.
Timmers C; Grompe M
Hum Mutat; 1996; 7(4):367-9. PubMed ID: 8723690
[No Abstract] [Full Text] [Related]
2. A single mutation of the fumarylacetoacetate hydrolase gene in French Canadians with hereditary tyrosinemia type I.
Grompe M; St-Louis M; Demers SI; al-Dhalimy M; Leclerc B; Tanguay RM
N Engl J Med; 1994 Aug; 331(6):353-7. PubMed ID: 8028615
[TBL] [Abstract][Full Text] [Related]
3. Hereditary tyrosinemia type 1: novel missense, nonsense and splice consensus mutations in the human fumarylacetoacetate hydrolase gene; variability of the genotype-phenotype relationship.
Ploos van Amstel JK; Bergman AJ; van Beurden EA; Roijers JF; Peelen T; van den Berg IE; Poll-The BT; Kvittingen EA; Berger R
Hum Genet; 1996 Jan; 97(1):51-9. PubMed ID: 8557261
[TBL] [Abstract][Full Text] [Related]
4. Mutations of the fumarylacetoacetate hydrolase gene in four patients with tyrosinemia, type I.
Grompe M; al-Dhalimy M
Hum Mutat; 1993; 2(2):85-93. PubMed ID: 8318997
[TBL] [Abstract][Full Text] [Related]
5. Identification of a stop mutation in five Finnish patients suffering from hereditary tyrosinemia type I.
St-Louis M; Leclerc B; Laine J; Salo MK; Holmberg C; Tanguay RM
Hum Mol Genet; 1994 Jan; 3(1):69-72. PubMed ID: 8162054
[TBL] [Abstract][Full Text] [Related]
6. Rapid nonradioactive assay for the detection of the common French Canadian tyrosinemia type I mutation.
Grompe M; al-Dhalimy M
Hum Mutat; 1995; 5(1):105. PubMed ID: 7728147
[No Abstract] [Full Text] [Related]
7. Two novel mutations involved in hereditary tyrosinemia type I.
St-Louis M; Poudrier J; Phaneuf D; Leclerc B; Laframboise R; Tanguay RM
Hum Mol Genet; 1995 Feb; 4(2):319-20. PubMed ID: 7757089
[No Abstract] [Full Text] [Related]
8. Tyrosinemia type 1--complex splicing defects and a missense mutation in the fumarylacetoacetase gene.
Rootwelt H; Kristensen T; Berger R; Høie K; Kvittingen EA
Hum Genet; 1994 Sep; 94(3):235-9. PubMed ID: 8076937
[TBL] [Abstract][Full Text] [Related]
9. Spectrum of mutations in the fumarylacetoacetate hydrolase gene of tyrosinemia type 1 patients in northwestern Europe and Mediterranean countries.
Bergman AJ; van den Berg IE; Brink W; Poll-The BT; Ploos van Amstel JK; Berger R
Hum Mutat; 1998; 12(1):19-26. PubMed ID: 9633815
[TBL] [Abstract][Full Text] [Related]
10. Fumarylacetoacetase mutations in tyrosinaemia type I.
Rootwelt H; Høie K; Berger R; Kvittingen EA
Hum Mutat; 1996; 7(3):239-43. PubMed ID: 8829657
[TBL] [Abstract][Full Text] [Related]
11. Mutations in the fumarylacetoacetate hydrolase gene causing hereditary tyrosinemia type I: overview.
St-Louis M; Tanguay RM
Hum Mutat; 1997; 9(4):291-9. PubMed ID: 9101289
[TBL] [Abstract][Full Text] [Related]
12. Heterozygosity for an exon 12 splicing mutation and a W234G missense mutation in an American child with chronic tyrosinemia type 1.
Hahn SH; Krasnewich D; Brantly M; Kvittingen EA; Gahl WA
Hum Mutat; 1995; 6(1):66-73. PubMed ID: 7550234
[TBL] [Abstract][Full Text] [Related]
13. Frequency of the IVS12 + 5G-->A splice mutation of the fumarylacetoacetate hydrolase gene in carriers of hereditary tyrosinaemia in the French Canadian population of Saguenay-Lac-St-Jean.
Poudrier J; St-Louis M; Lettre F; Gibson K; Prévost C; Larochelle J; Tanguay RM
Prenat Diagn; 1996 Jan; 16(1):59-64. PubMed ID: 8821854
[TBL] [Abstract][Full Text] [Related]
14. Simple detection of a (Finnish) hereditary tyrosinemia type 1 mutation.
St-Louis M; Poudrier J; Tanguay RM
Hum Mutat; 1996; 7(4):379-80. PubMed ID: 8723698
[No Abstract] [Full Text] [Related]
15. Type 1 hereditary tyrosinemia. Evidence for molecular heterogeneity and identification of a causal mutation in a French Canadian patient.
Phaneuf D; Lambert M; Laframboise R; Mitchell G; Lettre F; Tanguay RM
J Clin Invest; 1992 Oct; 90(4):1185-92. PubMed ID: 1401056
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the human fumarylacetoacetate hydrolase gene and identification of a missense mutation abolishing enzymatic activity.
Labelle Y; Phaneuf D; Leclerc B; Tanguay RM
Hum Mol Genet; 1993 Jul; 2(7):941-6. PubMed ID: 8364576
[TBL] [Abstract][Full Text] [Related]
17. Walking the ethical highwire: genetic screening and hereditary tyrosinemia.
Romero R; Lavine JE
Hepatology; 1995 Apr; 21(4):1193-5. PubMed ID: 7705795
[No Abstract] [Full Text] [Related]
18. Two missense mutations causing tyrosinemia type 1 with presence and absence of immunoreactive fumarylacetoacetase.
Rootwelt H; Chou J; Gahl WA; Berger R; Coşkun T; Brodtkorb E; Kvittingen EA
Hum Genet; 1994 Jun; 93(6):615-9. PubMed ID: 8005583
[TBL] [Abstract][Full Text] [Related]
19. Purification of mRNA coding for the enzyme deficient in hereditary tyrosinemia, fumarylacetoacetate hydrolase.
Nicole LM; Valet JP; Laberge C; Tanguay RM
Biochem Cell Biol; 1986 May; 64(5):489-93. PubMed ID: 3718716
[TBL] [Abstract][Full Text] [Related]
20. Novel splice, missense, and nonsense mutations in the fumarylacetoacetase gene causing tyrosinemia type 1.
Rootwelt H; Berger R; Gray G; Kelly DA; Coşkun T; Kvittingen EA
Am J Hum Genet; 1994 Oct; 55(4):653-8. PubMed ID: 7942842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
